Search Within

Malin Lisa Hultcrantz

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (21)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (62)
  2. Department of Medicine (62)
  3. Department of Pathology and Laboratory Medicine (62)
  4. Hematologic Malignancies, Division of (62)
  5. Myeloma (62)
  6. Sloan Kettering Institute Postdocs (62)

More Groups

People
  1. Sham Mailankody (46)
  2. Alexander Lesokhin (45)
  3. Neha Korde (44)
  4. Hani Hassoun (42)
  5. Heather Landau (41)
  6. Urvi Shah (39)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (11)
  4. 2022 (6)
  5. 2021 (10)
  6. 2020 (11)

More Years

Publications
  1. Blood (28)
  2. Clinical Lymphoma, Myeloma and Leukemia (9)
  3. Blood Cancer Journal (3)
  4. Journal of Clinical Oncology (3)
  5. Nature Communications (3)
  6. American Journal of Hematology (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. Elsevier Inc. (10)
  3. Nature Publishing Group (6)
  4. American Association for Cancer Research (3)
  5. American Society of Clinical Oncology (3)
  6. American Medical Association (2)

More Publishers

Results (62)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
    Journal Article

    Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save